RxDoctor Payments Data

Shahid Shamim, MD

Internal Medicine · Rockville, MDNPI 1932208543

Payments from drug & device makers

$8,891in general payments, 2019–2025

Across 373 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$758
  • GSK$557
  • Amgen$518
  • Pfizer$473
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,77999%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,891 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$380,400
Medicare patients
793
Services billed
6,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$179,878
EliquisApixaban93$104,933
MounjaroTirzepatide60$73,968
JardianceEmpagliflozin48$61,843
AdcircaTadalafil11$44,953
Tresiba Flextouch U-200Insulin Degludec42$42,672
FarxigaDapagliflozin Propanediol35$40,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$22,864
LinzessLinaclotide13$19,797
Synjardy XrEmpagliflozin/Metformin Hcl18$17,148
WegovySemaglutide11$16,920
XareltoRivaroxaban23$15,022
Rosuvastatin Calcium386$8,410
Atorvastatin Calcium601$7,968
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,162$196,798128 claims
PfizerEliquis, Paxlovid$473$107,699110 claims
Boehringer IngelheimJardiance, Synjardy Xr$343$78,99166 claims
Lilly USA, LLCMounjaro$389$73,96860 claims
AstraZenecaFarxiga$2,076$40,51835 claims
GSKTrelegy Ellipta, Anoro Ellipta$557$29,69352 claims
AbbVieLinzess, Synthroid$758$24,845100 claims
Johnson & JohnsonXarelto$34$15,02223 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$33$5,764513 claims
Almatica Pharma LLCSertraline Hcl$18$1,880110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →